Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 6:49:100852.
doi: 10.1016/j.ctro.2024.100852. eCollection 2024 Nov.

Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives

Affiliations
Review

Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives

E Prades-Sagarra et al. Clin Transl Radiat Oncol. .

Abstract

Immunotherapy has revolutionized the field of cancer treatment, changing the standard of care to the use of immune checkpoint inhibitors. Radiotherapy can boost anti-tumour immune responses by changing the tumour microenvironment, but it also can cause radiotherapy-induced lymphopenia (RIL), a decrease in circulating lymphocyte counts. RIL has been associated with lower survival in patients undergoing radiotherapy, and new studies have suggested that it can also affect immunotherapy outcome. To study RIL's effects and to explore mitigation treatment strategies, preclinical models closely mimicking the clinical situation are needed. State-of-the-art image-guided small animal irradiators now offer the possibility to target specific organs in small animals to induce RIL, aiding research on its molecular mechanisms and prevention. This review covers the relationship between radiotherapy and RIL, its impact on patient survival, and future directions to generate models to investigate and prevent RIL.

Keywords: Immunotherapy; Preclinical models; Radiation-induced lymphopenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: L.J.D. has, outside of the submitted work, shares in the companies Convert Pharmaceuticals and LivingMed Biotech, he is co-inventor of a non-issued patent on LSRT (N2024889). The other authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Example of an irradiation plan targeting thoracic vertebrae to develop murine RIL models. (Left) Representative example of mouse chest CT image with a treatment plan designed with the software smART-ATP (SmART Scientific Solutions B.V.). Three 5 mm square beams were positioned to target the thoracic vertebrae, each consisting of two 1 Gy parallel opposed lateral beams. Dose deposition is shown by colour scale. (Right) Resulting cumulative dose-volume histogram for treatment plan depicted in left panel, indicating a maximal coverage of the target region, while a minimal dose to surrounding tissues.
Fig. 2
Fig. 2
Strategies currently under investigation to prevent, reverse or mitigate RIL. Created with BioRender.com.
Fig. 3
Fig. 3
Roadmap for the study of the effects of RIL on tumour progression and strategies to prevent or reverse it to improve patient survival. RT − radiotherapy; IT − immunotherapy. Created with BioRender.com.

Similar articles

Cited by

References

    1. Dobosz P., Dzieciątkowski T. The Intriguing History of Cancer Immunotherapy. Front Immunol. 2019;10:2965. - PMC - PubMed
    1. Kirkwood J.M., et al. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62(5):309–335. - PMC - PubMed
    1. Lesterhuis W.J., Haanen J.B.A.G., Punt C.J.A. Cancer immunotherapy – revisited. Nat Rev Drug Discov. 2011;10(8):591–600. - PubMed
    1. Marcus D., et al. Charged particle and conventional radiotherapy: current implications as partner for immunotherapy. Cancers (basel) 2021;13(6) - PMC - PubMed
    1. Sharma P., Allison J.P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–214. - PMC - PubMed

LinkOut - more resources